[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641420":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":35,"collaborators":37,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":26,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":26,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":26,"overallStatus":64,"whyStopped":26,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":26},{"fullName":5,"class":6},"First Affiliated Hospital of Wenzhou Medical University","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"treatment group","EXPERIMENTAL","The treatment group will be administered dotinurad 2 mg\u002Fday, colchicine 1 mg\u002Fday, and etoricoxib 120 mg\u002Fday (for 1-3 days) or 60 mg\u002Fday(for 4-7 days) for a duration of 4 weeks.",[13,14,15],"Drug: Dotinurad","Drug: colchicine","Drug: etoricoxib",{"label":17,"type":10,"description":18,"interventionNames":19},"Control group","The control group will be administered colchicine 1 mg\u002Fday, and etoricoxib 120 mg\u002Fday (for 1-3 days) or 60 mg\u002Fday(for 4-7 days) for 2 weeks. Then the control group will be administered dotinurad 2mg\u002Fday, colchicine 1 mg\u002Fday for 2 weeks.",[13,14,15],[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dotinurad","The drug used in the treatment group (from week 1 to 4)and the control group (from week 3 to 4). This is the main intervention factor of the study.",[17,9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"colchicine","The drugs used throughout the treatment and control groups. In this design, it is part of the background treatment or the standard treatment.",[17,9],{"type":22,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"etoricoxib","The drugs used by the treatment group and the control group in the first week. It is also part of the background treatment.",[17,9],{"type":36,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[38,41,43],{"name":39,"class":40},"The Affiliated People's Hospital of Ningbo University","OTHER_GOV",{"name":42,"class":6},"Wenzhou Central Hospital",{"name":44,"class":6},"Yuyao People's Hospital","100641420","phase-4-the-impact-of-initiating-dotinurad-urate-lowering-therapy-at-different-time-windows-on-gout-flare-resolution-time-100641420",false,"NCT07661030","The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time","The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time: A Multicenter, Randomized, Parallel-Controlled Study","Inclusion Criteria:\n\n* Male or female individuals aged 18-70 years old.\n* Meet the 2015 ACR\u002FEULAR diagnostic criteria of gout.\n* With an onset of acute gout flares within 7 days.\n* With gout experiencing gout flares ≥2 times; or with gout experiencing gout flares 1 time and is younger than 40 years old; or with gout experiencing gout flares 1 time and has a serum uric acid level greater than 480 μmol\u002FL and\u002For has co-morbidities (renal function impairment, hypertension,).\n* Provide a signed written informed consent form.\n\nExclusion Criteria:\n\n* Has secondary hyperuricemia.\n* Serum uric acid level \\\u003C 360 μmol\u002FL.\n* Used IL-1β inhibitors within 6 months before screening.\n* Used uric acid-lowering drugs within 1 month before screening.\n* Used anti-inflammatory drugs within 14 days before screening.\n* Comorbidities with nephrolithiasis or clinical urinary calculi\n* History of kidney transplantation or dialysis.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m².\n* AST or ALT \\> 2 times the upper limit of normal.\n* Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg during the screening period.\n* White blood cell count \\\u003C 3.5 × 10⁹\u002FL, or platelet count \\\u003C 100 × 10⁹\u002FL, or hemoglobin \\\u003C 90 g\u002FL.\n* Currently in the treatment period of malignant tumors, or within 6 months after the end of the treatment period.\n* Congestive heart failure (New York Heart Association \\[NYHA\\] cardiac function classification II-IV), confirmed ischemic heart disease, peripheral artery disease and\u002For cerebrovascular disease (including patients who have recently undergone coronary artery bypass grafting or angioplasty).\n* Hypersensitivity to the study drugs or their excipients, or all of urine alkalinizer (potassium citrate\u002Fsodium citrate hydrate compound preparations).\n* Have active gastrointestinal ulcers\u002Fbleeding, or have had a recurrence of ulcers\u002Fbleeding in the past.","ALL","18 Years","70 Years",{"count":56,"type":57},142,"ESTIMATED","INTERVENTIONAL",[60],"PHASE4","To confirm that initiating Dotinurad for uric acid uric acid lowering during the acute phase of gout is non-inferior to initiating it after the acute phase of gout has subsided, and to analyze whether initiating Dotinurad treatment during the acute phase will increase the pain level, the recurrence rate of gout, and the inflammatory level of patients.",[63],"Gout","NOT_YET_RECRUITING","2026-06-16",{"date":67,"type":68},"2026-06-22","ACTUAL",{"date":70,"type":57},"2026-07-30",{"date":72,"type":57},"2027-07-30",{"name":5,"class":6}]